Diagnostic Stewardship for Ventilator Associated Pneumonia
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, Houston, and Richmond, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- People taking part
- 161 people enrolled
- Started
- 21 Aug 2023
- Ended
- 30 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Modified lab reporting
- Record updated
- 24 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient located on ICU unit included in the study
- Patient is mechanically ventilated
- Patient had respiratory culture sent >48 hours after admission
- Patient age ≥ 18 years
Who cannot take part
- <6 months from solid organ transplant (SOT) OR <6 months from treatment for acute rejection following SOT
- Receiving lymphodepleting chemotherapy
- Autologous stem cell transplants or chimeric antigen receptor T-cell (CAR-T) therapy <6 months out
- Allogeneic stem cell transplant with graft vs host disease (GVHD) or receiving 2 or more immunosuppressants
- Receiving biologics within 6 months
- Heart or lung transplant
- Active treatment for lymphoreticular malignancies
- Advanced or untreated human immunodeficiency virus (HIV) infection with CD4 < 200
- Extra corporeal membrane oxygenation (ECMO) at time of respiratory culture
- Culture rejected by lab per standard lab protocol
- Prisoners
- Severe immunosuppression as defined by:
- Neutropenic < 1000
- Allogeneic stem cell transplants <6 months
Where in United States
- University of MarylandBaltimore, United States
- Baylor College of MedicineHouston, United States
- Virginia Commonwealth UniversityRichmond, United States
About the trial
What the trial wants to find out
The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associated pneumonia (VAP). The main question it aims to answer is: Does a modified culture reporting intervention reduce unnecessary antibiotics for ventilated patients in the intensive care unit (ICU)? Researchers will compare antibiotic use outcomes between eligible patients whose test results are communicated using the modified reporting and those with standard reporting of results.
The 2 groups in the trial
- Control PeriodNo study treatment, for comparison
Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).
- InterventionOther group
The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora). The modified report will include the likelihood of colonization instead of reporting bacterial identification.
Treatment: Modified lab reporting
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Diagnostic Stewardship for Ventilator Associated Pneumonia: A Pragmatic Cluster-randomized Crossover Trial of a Hybrid Order-review and Laboratory Reporting Intervention
- Record updated
- 24 November 2025